Search bioRxiv⌕ Search

Biology subjects

P, K. K.

Publications and source records attributed to P, K. K..

3 recordsLinked to original sources

HIPK2-and IKKβ-dependent phosphorylation stabilizes TAp63α during the oocyte DNA damage response

TAp63, a member of the p53 family, serves as a central quality control factor in oocytes, safeguarding genomic integrity during the prolonged dictyate arrest of meiosis. In healthy oocytes, TAp63 is maintained in an inactive dimeric state; upon DNA damage, it undergoes phosphorylation-dependent tetramerization, enabling transcriptional activation of pathways that determine oocyte fate. While the upstream activation cascade of TAp63 has been well characterized, the mechanisms that regulate its stability during the DNA damage response remain incompletely understood. Here, we identify the kinases HIPK2 and IKK{beta} as key regulators of TAp63 stability. We show that TAp63 interacts with both kinases and is phosphorylated at distinct residues, T452 by HIPK2 and S4/S12 by IKK{beta} in vitro and in vivo, in addition to previously described CHK2 and CK1-mediated phosphorylation. Functionally, these phosphorylation events do not primarily contribute to activation, but instead stabilize TAp63 by limiting MDM4-dependent ubiquitination and subsequent proteasomal degradation. Mechanistically, our data support a model in which CHK2 and CK1 initiate TAp63 phosphorylation, while HIPK2 and IKK{beta} act in a complementary manner to maintain protein stability during genotoxic stress. Disruption of HIPK2 or IKK{beta} activity reduces TAp63 stability, whereas their inhibition in vivo attenuates oocyte loss following DNA damage, resulting in increased preservation of the follicle pool. Importantly, these effects are observed across multiple systems, including mouse models and ex vivo goat ovary cultures, supporting an evolutionarily conserved role for this regulatory axis. Together, our findings uncover a previously unidentified layer of TAp63 regulation, in which phosphorylation not only contributes to its activation but also enhances protein stability, thereby fine-tuning oocyte responses to DNA damage. Our results further indicate that HIPK2 and IKK{beta}-mediated phosphorylation modulates oocyte survival under genotoxic stress, highlighting this pathway as a potential target for strategies aimed at limiting oocyte loss.

cell biology↗

Lipid Droplet Remodeling Safeguards Redox Balance through the DGAT1-PANK2-NRF2 Axis in Mammalian Oocytes and Drives Age-Associated Decline

How lipid droplets (LDs) buffer metabolic stress and redox imbalance in aging oocytes remains poorly understood. Here, we identify de novo LD remodeling as a metabolic capacitor that couples lipid storage to mitochondrial fitness and oxidative resilience in mammalian oocytes. Live imaging revealed pronounced LD dynamics, with LD number peaking at metaphase I and declining by metaphase II, while LD area shifted inversely. Despite stable triacylglyceride and free fatty acid pools, {beta}-oxidation increased sharply, indicating elevated lipid turnover during meiotic progression. Spatial mapping and fatty-acid tracing demonstrated that newly synthesized lipids are actively incorporated into LDs, which arise primarily from the endoplasmic reticulum and engage with lysosomes and mitochondria. Acute inhibition of DGAT1, the rate-limiting enzyme of LD biogenesis, disrupted meiotic maturation and triggered oxidative stress, mitochondrial aggregation, and ultrastructural damage. Proteomic profiling revealed robust PANK2 upregulation and suppression of NRF2-linked antioxidant pathways. Mechanistic analyses showed that {beta}-oxidation blockade, PANK2 inhibition, antioxidant supplementation, or NRF2 activation each partially rescued DGAT1-dependent defects, and genetic validation in NRF2-null oocytes confirmed pathway dependence. Notably, aged oocytes exhibited reduced de novo LD biogenesis and impaired DGAT1-ER organization despite increased LD accumulation, resulting in smaller, metabolically inert droplets and a mismatch between lipid formation and utilization. Inhibiting PANK2 alleviated oxidative stress in aged oocytes, further implicating the DGAT1-PANK2-NRF2 axis in redox control and oocyte quality. Together, these findings establish LD biogenesis as a core metabolic capacitor safeguarding mitochondrial and organelle integrity during meiosis and reveal dysfunction of the DGAT1-PANK2-NRF2 axis as a mechanistic driver of reproductive aging.

cell biology↗

Engineered RVG29-Conjugated Chitosan for Enhanced Brain Delivery of Kisspeptin Agonists and Antagonists in Reproductive Health.

Efficient delivery of intact therapeutic peptides across the blood-brain barrier (BBB) remains a central obstacle in translating neuroendocrine modulators to clinical practice. Kisspeptin receptor (KISS1R) agonists and antagonists precisely regulate gonadotropin-releasing hormone (GnRH) pulsatility, thereby controlling luteinizing hormone (LH) release, steroidogenesis, and fertility. While the KISS1R agonist KP10 accelerates GnRH-LH pulses to promote ovulation, the antagonist KP234 suppresses pulse generation, inducing reversible infertility. However, their poor BBB permeability limits clinical application. Here, we engineered a non-invasive brain delivery platform by covalently coupling the rabies virus glycoprotein-derived peptide RVG29 to oxidized chitosan nanoparticles via Schiff base chemistry. Sodium periodate oxidation introduced aldehyde groups, FT-IR confirmed aldehyde formation, and UV-Vis spectroscopy validated RVG29 conjugation through characteristic absorbance shifts. The resulting RVG29 - chitosan carriers demonstrated biocompatibility, enhanced neuronal uptake [~]2.1-fold in vitro, and achieved [~]2.5-fold higher brain accumulation in vivo compared to unconjugated controls. Systemic delivery of RVG29-chitosan-KP10 restored and amplified LH pulsatility in ovariectomized mice, accelerated estrous cycling, increased preovulatory follicle numbers, and enhanced litter size. In contrast, RVG29-chitosan-KP234 abolished LH pulses, maintained animals in persistent diestrus, depleted corpora lutea, and produced complete yet reversible infertility. Longitudinal dosing demonstrated stable neuroendocrine modulation without systemic toxicity, and ovarian histology confirmed ovulatory arrest in antagonist-treated animals. By enabling programmable, bidirectional control of a central hypothalamic circuit through systemic delivery of unmodified peptides, this platform addresses a long-standing barrier in neuroendocrine therapeutics. Beyond fertility regulation, this approach can be adapted to other hypothalamic-driven processes, including metabolic, stress-axis, and circadian control.

bioengineering↗